NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Unconfirmed

**Date:** Tuesday 10 October 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all items
2. Iftab Akram Present for all items
3. Dr Alex Cale Present for items 1.1 to 4.2.2
4. Michael Chambers Present for all items
5. Dawn Cooper Present for all items
6. Dr Mark Corbett Present for all items
7. Dr Prithwiraj Das Present for items 1.1 to 4.2.2 and

5.1.2 to 5.2.2

1. Chamkhor Dhillon Present for all items
2. Dr David Foreman Present for all items
3. Dr Rob Forsyth Present for all items
4. Dr Pedro Saramago Goncalves Present for all items
5. Dr Nigel Langford Present for all items
6. Dr Steven Lloyd Present for all items
7. Iain McGowan Present for all items
8. Ugochi Nwulu Present for all items
9. Stella O’Brien Present for all items
10. Dr Clare Offer Present for all items
11. Amit Parekh Present for all items
12. Dr Kate Ren Present for all items
13. Professor Andrew Renehan Present for all items
14. Dr Britta Stordal Present for items 5.1 to 5.2.2
15. Elizabeth Thurgar Present for all items
16. Dr Satish Venkateshan Present for items 5.1 to 5.2.2

NICE staff (key players) present

Ross Dent, Associate Director Items 1.1 to 4.2.2

Louise Jafferally, Project Manager Items 1.1 to 4.2.2

Lizzie Walker, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

Heather Stegenga, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Jasdeep Hayre, Associate Director Items 5.1 to 5.2.2

Celia Mayers, Project Manager Items 5.1 to 5.2.2

Victoria Kelly, Heath Technology Assessment Adviser Items 5.1 to 5.2.2

Giacomo De Guisa, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

External assessment group representatives present

Mariana Bacelar, BMJ Group Items 1.1 to 4.1.3

Nicole Downes, BMJ Group Items 1.1 to 4.1.3

Graham Scotland, Aberdeen HTA Group Items 5.1 to 5.1.3

David Cooper, Aberdeen HTA Group Items 5.1 to 5.1.3

Clinical, Patient & NHS England experts present

Professor Peter Clark, CDF Clinical Lead, NSHE Items 1.1 to 4.2.2

Associate Professor David Lewis, Consultant Haematologist, NCRI-ACP-RCP-RCR Items 1.1 to 4.1.3

Dr Wendy Osborne, Consultant Haematologist, Royal College of Pathologists Items 1.1 to 4.1.3

Chiara Braconi, Chair in HepatoBiliary Oncology/Consultant Medical Oncologist, Servier Items 5.1 to 5.1.3

John Bridgewater, Professor and Honorary Consultant in Medical Oncology, Cholangiocarcinoma UK & NCRI-ACP-RCP-RCR Items 5.1 to 5.1.3

Helen Morement, Founder & CEO of AMMF, Cholangiocarcinoma UK Items 5.1 to 5.1.3

Andrew Clay, patient expert, AMMF Items 5.1 to 5.1.3

Observers present

Jacoline Bouvy, Programme Director, NICE Items 1.1 to 4.2.2

Milena Wobbe, Technical Analyst, NICE Items 1.1 to 4.2.2

Sana Issa, Coordinator for the public, NICE Items 5.1 to 5.1.3

Emily Crowe, Principal Technical Adviser, NICE Items 5.1 to 5.1.3

Federica Ciamponi, Scientific Adviser, NICE Items 5.1 to 5.2.2

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. Steve O’Brien welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Dr Arpit Srivastava, John Hampson, Dr Richard Nicholas.

### News and announcements

* 1. We welcome new members Satish Venkateshan and Amit Parekh who are observing this meeting.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 12 September 2023.

### Appraisal of: Epcoritamab for treating relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments [ID4045]

* 1. Part 1 – Closed session - The Medicines and Healthcare products Regulatory Agency (MHRA) has not yet given its regulatory opinion for this appraisal and therefore this discussion will take place in a part 2 session (part 2 sessions are closed to public observers).
     1. The chair welcomed the invited experts, external assessment group representatives and company representatives from AbbVie.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10931/documents).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Professor Andrew Renehan (clinical lead), Dr Pedro Saramago Goncalves (cost lead) and Stella O’Brien (lay lead).
  2. Part 2a – Closed session (company representatives, clinical experts and external assessment group representatives were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached through a vote by members.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: [Project information | Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments [ID4045] | Guidance | NICE](https://www.nice.org.uk/guidance/indevelopment/gid-ta10931).

### Appraisal of Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 mutation after at least 1 therapy [ID6164]

* 1. Part 1 – Open session
     1. Steve O’Brien welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Servier Labs.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11113/documents).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Britta Stordal (clinical lead), Michael Chambers (cost lead), Ugochi Nwulu (lay lead).
  2. Part 2a – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: [Project information | Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 mutation after at least 1 therapy [ID6164] | Guidance | NICE](https://www.nice.org.uk/guidance/indevelopment/gid-ta11113)

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Tuesday 14 November 2023 and will start promptly at 9.00am.